Search Results for "f"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for f. Results 21 to 30 of 858 total matches.

In Brief: A New Hib Booster

   
The Medical Letter on Drugs and Therapeutics • Nov 02, 2009  (Issue 1324)
., M.P.H., F.A.C.P., Harvard Medical School EDITOR: Jean-Marie Pflomm, Pharm.D. ASSISTANT EDITORS ...
In 2007, Merck voluntarily recalled some lots of PedvaxHIB and Comvax, two Haemophilus influenzae type b (Hib) vaccines, and temporarily stopped their production because of possible contamination, resulting in a shortage during which pediatricians were urged to defer giving Hib booster doses (normally given at 12-15 months) to healthy children. Now the FDA has granted accelerated licensure of Hiberix (GlaxoSmithKline), a monovalent vaccine conjugated with tetanus toxoid that has been used in Europe since 1996, as a booster (final) dose of the Hib series in children 15 months-4 years old....
Med Lett Drugs Ther. 2009 Nov 2;51(1324):88 |  Show IntroductionHide Introduction

Correction: Ferumoxytol (Feraheme)

   
The Medical Letter on Drugs and Therapeutics • Apr 19, 2010  (Issue 1336)
. EXECUTIVE EDITOR: Gianna Zuccotti, M.D., M.P.H., F.A.C.P., Harvard Medical School EDITOR: Jean-Marie ...
In the Medical Letter article on Ferumoxytol (Feraheme) - A New Parenteral Iron Formulation (2010; 52:23), the last sentence of the Dosage, Administration and Cost paragraph should have listed the cost of 1 gram of sodium ferric gluconate (Ferrlecit) as about $600.
Med Lett Drugs Ther. 2010 Apr 19;52(1336):32 |  Show IntroductionHide Introduction

In Brief: Plan B for 17-Year Olds

   
The Medical Letter on Drugs and Therapeutics • May 18, 2009  (Issue 1312)
., M.P.H., F.A.C.P., Harvard Medical School EDITOR: Jean-Marie Pflomm, Pharm.D. ASSISTANT EDITORS ...
The FDA has announced that it will lower the age for over-the-counter access to the emergency contraceptive Plan B1 from 18 to 17 years old. In a randomized, controlled trial, the two 0.75-mg levonorgestrel tablets in Plan B, taken 12 hours apart beginning within 72 hours after unprotected intercourse, decreased the overall pregnancy rate to 1.1% (11/976) of women who requested emergency contraception.2 The sooner the drug is taken after coitus, the more effective it is. Nausea and vomiting can occur with Plan B. Fetal malformations have not been associated with pregnancies that occurred...
Med Lett Drugs Ther. 2009 May 18;51(1312):40 |  Show IntroductionHide Introduction

In Brief: Injectable Paliperidone Palmitate for Schizophrenia

   
The Medical Letter on Drugs and Therapeutics • Nov 02, 2009  (Issue 1324)
., M.P.H., F.A.C.P., Harvard Medical School EDITOR: Jean-Marie Pflomm, Pharm.D. ASSISTANT EDITORS ...
Paliperidone palmitate (Invega Sustenna – Ortho-McNeil Janssen) has been approved by the FDA as a once-monthly injection for acute and maintenance treatment of schizophrenia in adults. An extended-release oral formulation (Invega) has been available since 2006.1 Long-acting injections of antipsychotic drugs typically are used to treat patients who cannot adhere to an oral regimen.2,3 Paliperidone is the primary active metabolite of risperidone (Risperdal), which is also available as a long-acting (every 2 weeks) injection. It is unclear whether either risperidone or paliperidone is a better...
Med Lett Drugs Ther. 2009 Nov 2;51(1324):88 |  Show IntroductionHide Introduction

Which TNF Inhibitor for Rheumatoid Arthritis?

   
The Medical Letter on Drugs and Therapeutics • May 17, 2010  (Issue 1338)
for rheumatoid arthritis. Med Lett Drugs Ther 1998; 40:110. 4. F Tubach et al. Risk of tuberculosis is higher ...
The FDA has approved five tumor necrosis factor (TNF) inhibitors for treatment of moderately to severely active rheumatoid arthritis (RA). TNF-α is a pro-inflammatory cytokine involved in the pathogenesis of many systemic inflammatory disorders.
Med Lett Drugs Ther. 2010 May 17;52(1338):38-9 |  Show IntroductionHide Introduction

In Brief: Tamoxifen and SSRI Interactions

   
The Medical Letter on Drugs and Therapeutics • Jun 15, 2009  (Issue 1314)
., M.P.H., F.A.C.P., Harvard Medical School EDITOR: Jean-Marie Pflomm, Pharm.D. ASSISTANT EDITORS ...
Use of a selective serotonin reuptake inhibitor (SSRI) is common in women taking tamoxifen (Nolvadex, and others) for breast cancer, both to treat depression and to decrease hot flashes. However, tamoxifen must be metabolized by CYP2D6 to become pharmacologically fully active (MJ Higgins et al. J Natl Compr Canc Netw 2009; 7:203), and the SSRIs fluoxetine (Prozac, and others) and paroxetine (Paxil, and others) are strong inhibitors of CYP2D6. Sertraline (Zoloft, and others) inhibits CYP2D6 to a lesser extent. Citalopram (Celexa, and others) and escitalopram (Lexapro), the 2 other SSRIs...
Med Lett Drugs Ther. 2009 Jun 15;51(1314):45-6 |  Show IntroductionHide Introduction

In Brief: Poor Metabolizers of Clopidogrel (Plavix)

   
The Medical Letter on Drugs and Therapeutics • May 03, 2010  (Issue 1337)
., M.P.H., F.A.C.P., Harvard Medical School EDITOR: Jean-Marie Pflomm, Pharm.D. ASSISTANT EDITORS ...
The FDA has required the manufacturer of Plavix, an antiplatelet drug used in addition to aspirin to prevent cardiovascular events in high-risk patients,1 to add a boxed warning to the package insert about the risk of a poor response to the drug in patients with genetic polymorphisms of the cytochrome P450 enzyme CYP2C19. Clopidogrel is a prodrug and CYP2C19 is mainly responsible for its bioactivation. The Medical Letter reported last year that several studies have found higher rates of cardiovascular events, including stent thrombosis, in patients with these polymorphisms taking...
Med Lett Drugs Ther. 2010 May 3;52(1337):33 |  Show IntroductionHide Introduction

In Brief: Velaglucerase (Vpriv) for Gaucher's Disease

   
The Medical Letter on Drugs and Therapeutics • May 03, 2010  (Issue 1337)
: Gianna Zuccotti, M.D., M.P.H., F.A.C.P., Harvard Medical School EDITOR: Jean-Marie Pflomm, Pharm.D ...
The FDA has approved velaglucerase alfa (Vpriv – Shire), a new formulation of glucocerebrosidase prepared from human fibroblasts, for treatment of the nonneurologic form of Gaucher’s disease (Type 1). Patients with Gaucher’s disease have a congenital deficiency of glucocerebrosidase that leads to accumulation of glucosylceramide, the end-product of sphingolipid catabolism, in the lysozymes of reticuloendothelial cells in the liver, spleen and bone marrow.Velaglucerase is the second form of the enzyme now available in the US; imiglucerase (Cerezyme – Genzyme), which is produced by...
Med Lett Drugs Ther. 2010 May 3;52(1337):36 |  Show IntroductionHide Introduction

In Brief: Only The Name Remains The Same

   
The Medical Letter on Drugs and Therapeutics • Jun 28, 2010  (Issue 1341)
EDITOR IN CHIEF: Mark Abramowicz, M.D. EXECUTIVE EDITOR: Gianna Zuccotti, M.D., M.P.H., F ...
A Medical Letter subscriber was surprised to discover that a new Citracal product contained not only calcium citrate, but also calcium carbonate. Citracal Plus Bone Density Builder actually contains more calcium carbonate per tablet than calcium citrate (240 mg vs. 60 mg). Another Citracal product, Citracal Plus Heart Health, also contains more calcium carbonate than calcium citrate. Many clinicians prefer calcium citrate because it can be taken with or without food, while calcium carbonate must be taken with food for optimal absorption. Other familiar over-the-counter (OTC) names also contain...
Med Lett Drugs Ther. 2010 Jun 28;52(1341):49 |  Show IntroductionHide Introduction

Bexsero - A Second Serogroup B Meningococcal Vaccine

   
The Medical Letter on Drugs and Therapeutics • Nov 23, 2015  (Issue 1482)
. meningitidis: 3 recombinant proteins (NadA, NHBA, and fHbp) and outer membrane vesicles expressing a fourth ...
The FDA has approved Bexsero (Novartis/GSK), a vaccine that protects against invasive meningococcal disease caused by Neisseria meningitidis serogroup B. It is the second serogroup B meningococcal vaccine to be approved in the US; Trumenba was the first. Both vaccines are approved for use in persons 10-25 years old. Bexsero is approved in Europe, Canada, and Australia for use in children as young as 2 months old.
Med Lett Drugs Ther. 2015 Nov 23;57(1482):158-9 |  Show IntroductionHide Introduction